Promising Chelator Research Articles

Golden Apple Snail Shell (<i>Pomacea canaliculata</i>) as Prospective Agent in Absorbing Lead (pb) in Water

Heavy metals such as cadmium (Cd), chromium (Cr), lead (Pb), and mercury (Hg) are considered to be highly intoxicating pollutants in water. This is a primary concern for developed countries like the Philippines since it creates a substantial impact on the environment and health. Absorption of these heavy metals has only been of limited use because it undergoes methods which are expensive. This research focuses on determining the probability of Golden Apple Snail (GAS) shells (Pomacea canaliculata) as a cost-effective treatment in absorbing heavy metal Lead (Pb) in water. A new chelating agent has been prepared by pulverizing GAS shells and weighing them as 20g per treatment, two factors are observed in the study: agitation time of 6, 12 and 18 hours and varying concentrations of 50, 100, and 150 ppm. The absorptive capacity of the bio-absorbent was measured and quantified using the Flame Atomic Absorption Spectroscopy (FLAAS) as well as the residue of the Lead (Pb) in the solution. The result of the analysis shows that the absorptive capacity of GAS shells are at 99.86% with the absorption capacity in regards of concentration are at 99.97% and with agitation time 99.96%. Furthermore, results show that Sample Ca2, having 50 ppm concentration being treated for 18 hours rendered a 100% absorption of the heavy metal in the solution. It can, therefore, be concluded that GAS shell is a promising chelating agent in absorbing Lead (Pb).

Unexpected Product of the Reaction of Iron(II) Dichloroclathrochelate with the [Fe2(μ-S)2(CO)6]2– Cluster Dianion: Synthesis and X-ray Diffraction Structure of the First Cage Complex with Thiol Groups Inherently Bonded to a Macrobicyclic Framework

An attempt to prepare a hybrid clusteroclathrochelate by nucleophilic substitution of iron(II) dichloroclathrochelate by substitution of its chlorine atoms with the [Fe2(μ-S)2(CO)6]2– cluster dianion as a nucleophilic agent generated in situ by the reduction of Fe2(μ-S2)(CO)6 with lithium triethylborohydride unexpectedly gave the macrobicyclic complex with two inherent thiol groups as the single clathrochelate product. Obviously, the initial iron-sulfide cluster underwent a complete decomposition during the reaction, thus acting only as a source of HS– and S2– anions. The composition and the structure of the complex obtained were confirmed by elemental analysis, MALDI-TOF mass spectrometry, 1H and 13C{1H} NMR spectroscopy, and single crystal X-ray diffraction (CIF file CCDC 1585112). The encapsulated iron(II) ion is located at the centre of its FeN6 coordination polyhedron possessing the geometry intermediate between a trigonal prism (the distortion angle φ = 0°) and a trigonal antiprism (φ = 60°) with φ ≈ 25°; the height of this polyhedron is 2.33 A. The presence of two thiol groups in the vicinal positions of the same ribbed moiety of the macrobicyclic molecule substantially affects the crystal packing of the molecular crystal containing clathrochelate dimers formed by four hydrogen bonds of two types (i.e., two S–H···O and two S–H···N bonds). The obtained cage complex and its deprotonated forms seem to be promising cis-disulfide bridging or chelating ligand synthons for the synthesis of new types of polynuclear complexes and coordination polymers as well.

Young herbaceous legumes – a natural reserve of bioactive compounds and antioxidants for healthy food and supplements

Young plants of clover (Trifolium pratense L. and T. medium L.), medick (Medicago sativa L. and M. lupulina L.), sainfoin (Onobrychis viciifolia Scop.) and milkvetch (Astragalus glycyphyllos L. and A. cicer L.), were investigated for total contents of phenolics, flavonoids, isoflavones, condensed tannins and triterpene saponins as well as their extracts for antiradical and ferrous ion chelating activity. The impact of two sample drying methods on the aforementioned characters was compared. The phytochemical concentrations were higher in the freeze-dried legumes; however, antioxidant activities were generally higher of oven-dried samples. Both the composition of health promoting phytochemicals and antioxidant properties were strongly species-dependent. Among the species tested, Trifolium spp. were most abundant in isoflavones, Medicago spp. – in saponins and O. viciifolia – in tannins. Plants of T. medium and O. viciifolia were rich in TPC. The extracts of T. pratense, O. viciifolia and A. cicer possessed significant antiradical activity; the extracts from Astragalus spp. proved to be promising chelators of ferrous ion. We concluded that young perennial legumes could be considered as potential candidates for the development of nutraceuticals and functional food ingredients to accommodate the need for a particular bioactive component or property.

Design, Synthesis, and Reactivity of Multidentate Ligands with Rhenium(I) and Rhenium(V) Cores

Synthetic pathways to a range of potentially N3O‐tetradentate ligands designed to coordinate to rhenium cores, as well as their coordination behaviors towards different rhenium cores (oxidation states +I and +V) are investigated. Two functionalized N‐{[1‐(4‐R)‐1H‐1,2,3‐triazol‐4‐yl]methyl}‐2‐(pyridin‐2‐ylmethoxy)aniline derivatives L1H (R = methyl acetate) and L2H (R = 4‐nitrophenyl) act exclusively as bidentate ligands and lead to the formation of mononuclear tricarbonylrhenium(I) complexes of the general formula [(LH)Re(CO)3Cl] with L = L1 or L2. Both complexes are characterized by 1H NMR and 13C NMR, FTIR spectroscopy, electrospray ionization mass spectrometry, and in the case of [(L2H)Re(CO)3Cl], single‐crystal X‐ray diffraction. The rhenium is coordinated by three carbonyl groups, a chlorine atom and two nitrogen atoms of a triazole group, and a nitrogen of the aniline ring of the ligand, respectively. A theoretical study shows complex [(L2H)Re(CO)3Cl] is the most stable structural isomer. In addition, the oxorhenium(V) complex [(L3)ReO] is isolated and fully characterized after the reaction of the ReV precursor [ReOCl3(PPh3)2] with L3H3 [methyl 2‐(4‐{[2‐(2‐hydroxyphenylamino)‐2‐oxoethylamino]methyl}‐1H‐1,2,3‐triazol‐1‐yl)acetate]. Its corresponding 99mTc complex was achieved with a good radiochemical yield (> 90 %). The convenient synthesis of this ligand, coupled with its high affinity for [ReO]3+ and [99mTcO]3+ cores, make it a promising chelator for biomedical applications.

P-NO2-Bn-H4neunpa and H4neunpa-Trastuzumab: Bifunctional Chelator for Radiometalpharmaceuticals and 111In Immuno-Single Photon Emission Computed Tomography Imaging.

Potentially nonadentate (N5O4) bifunctional chelator p-SCN-Bn-H4neunpa and its immunoconjugate H4neunpa-trastuzumab for 111In radiolabeling are synthesized. The ability of p-SCN-Bn-H4neunpa and H4neunpa-trastuzumab to quantitatively radiolabel 111InCl3 at an ambient temperature within 15 or 30 min, respectively, is presented. Thermodynamic stability determination with In3+, Bi3+, and La3+ resulted in high conditional stability constant (pM) values. In vitro human serum stability assays have demonstrated both 111In complexes to have high stability over 5 days. Mouse biodistribution of [111In][In(p-NO2-Bn-neunpa)]-, compared to that of [111In][In(p-NH2-Bn-CHX-A″-diethylenetriamine pentaacetic acid (DTPA))]2-, at 1, 4, and 24 h shows fast clearance of both complexes from the mice within 24 h. In a second mouse biodistribution study, the immunoconjugates 111In-neunpa-trastuzumab and 111In-CHX-A″-DTPA-trastuzumab demonstrate a similar distribution profile but with slightly lower tumor uptake of 111In-neunpa-trastuzumab compared to that of 111In-CHX-A″-DTPA-trastuzumab. These results were also confirmed by immuno-single photon emission computed tomography (immuno-SPECT) imaging in vivo. These initial investigations reveal the acyclic bifunctional chelator p-SCN-Bn-H4neunpa to be a promising chelator for 111In (and other radiometals) with high in vitro stability and also show H4neunpa-trastuzumab to be an excellent 111In chelator with promising biodistribution in mice.

Influence of a novel, versatile bifunctional chelator on theranostic properties of a minigastrin analogue.

Background6-[Bis(carboxymethyl)amino]-1,4-bis(carboxymethyl)-6-methyl-1,4-diazepane (AAZTA ) is a promising chelator with potential advantages over 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) for radiopharmaceutical applications. Its mesocyclic structure enables fast radiolabelling under mild conditions with trivalent metals including not only 68Ga for positron emission tomography (PET) but also 177Lu and 111In for single-photon emission computed tomography (SPECT) and radionuclide therapy. Here, we describe the evaluation of a bifunctional AAZTA derivative conjugated to a model minigastrin derivative as a potential theranostic agent.MethodsAn AAZTA derivative with an aliphatic C9 chain as linker was coupled to a minigastrin, namely [AAZTA0, D-Glu1, desGlu2–6]-minigastrin (AAZTA-MG), and labelled with 68Ga, 177Lu and 111In. The characterisation in vitro included stability studies in different media and determination of logD (octanol/PBS). Affinity determination (IC50) and cell uptake studies were performed in A431-CCK2R cells expressing the human CCK2 receptor. μPET/CT and ex vivo biodistribution studies were performed in CCK2 tumour xenograft-bearing nude mice and normal mice.ResultsAAZTA-MG showed high radiochemical yields for 68Ga (>95 %), 177Lu (>98 %) and 111In (>98 %). The logD value of −3.7 for both [68Ga]- and [177Lu]-AAZTA-MG indicates a highly hydrophilic character. Stability tests showed overall high stability in solution with some degradation in human plasma for [68Ga]- and transchelation towards DTPA for and [177Lu]-AAZTA-MG. An IC50 value of 10.0 nM was determined, which indicates a high affinity for the CCK2 receptor. Specific cell uptake after 60 min was >7.5 % for [68Ga]-AAZTA-MG and >9.5 % for [177Lu]-AAZTA-MG, comparable to other DOTA-MG-analogues. μPET/CT studies in CCK2 receptor tumour xenografted mice not only revealed high selective accumulation in A431-CCK2R positive tumours of 68Ga-labelled AAZTA-MG (1.5 % ID/g in 1 h post injection) but also higher blood levels as corresponding DOTA-analogues. The 111In-labelled peptide had a tumour uptake of 1.7 % ID/g. Biodistribution in normal mice with the [177Lu]-AAZTA-MG showed a considerable uptake in intestine (7.3 % ID/g) and liver (1.5 % ID/g).ConclusionOverall, AAZTA showed interesting properties as bifunctional chelator for peptides providing mild radiolabelling conditions for both 68Ga and trivalent metals having advantages over the currently used chelator DOTA. Studies are ongoing to further investigate in vivo targeting properties and stability issues and the influence of spacer length on biodistribution of AAZTA.Electronic supplementary materialThe online version of this article (doi:10.1186/s13550-015-0154-7) contains supplementary material, which is available to authorized users.

Mercury Complexes with Tripodal Pseudopeptides Derived from D ‐Penicillamine Favour a HgS 3 Coordination

The pseudopeptides L4 and L5 are built on a nitrilotriacetic scaffold and functionalized with three D-penicillamine (D-Pen) units. D-Pen is an interesting building block and a bulkier analogue of cysteine with the β-methylene hydrogen atoms replaced by larger methyl groups. The two sulfur ligands L4 and L5 are studied here with the toxic HgII ion. The formation of the two mononuclear complexes HgL4 and HgL5 is demonstrated by 1H NMR spectroscopy and mass spectrometry and the tristhiolato coordination is unambiguously evidenced by the UV absorption signatures. An important feature is the stabilization of the HgS3 coordination mode at the expense of the generally preferred HgS2 linear coordination. It appears that the hindered D-Pen pseudopeptide L5 is capable of stabilizing the unusual HgS3 coordination over a large pH range in water, pH > 5.5. This water-soluble compound can therefore be considered as a promising chelating agent for mercury detoxification.

Novel Bifunctional Cyclic Chelator for (89)Zr Labeling-Radiolabeling and Targeting Properties of RGD Conjugates.

Within the last years 89Zr has attracted considerable attention as long-lived radionuclide for positron emission tomography (PET) applications. So far desferrioxamine B (DFO) has been mainly used as bifunctional chelating system. Fusarinine C (FSC), having complexing properties comparable to DFO, was expected to be an alternative with potentially higher stability due to its cyclic structure. In this study, as proof of principle, various FSC-RGD conjugates targeting αvß3 integrins were synthesized using different conjugation strategies and labeled with 89Zr. In vitro stability, biodistribution, and microPET/CT imaging were evaluated using [89Zr]FSC-RGD conjugates or [89Zr]triacetylfusarinine C (TAFC). Quantitative 89Zr labeling was achieved within 90 min at room temperature. The distribution coefficients of the different radioligands indicate hydrophilic character. Compared to [89Zr]DFO, [89Zr]FSC derivatives showed excellent in vitro stability and resistance against transchelation in phosphate buffered saline (PBS), ethylenediaminetetraacetic acid solution (EDTA), and human serum for up to 7 days. Cell binding studies and biodistribution as well as microPET/CT imaging experiments showed efficient receptor-specific targeting of [89Zr]FSC-RGD conjugates. No bone uptake was observed analyzing PET images indicating high in vivo stability. These findings indicate that FSC is a highly promising chelator for the development of 89Zr-based PET imaging agents.

Effects of cadmium and monensin on renal and cardiac functions of mice subjected to subacute cadmium intoxication.

Cadmium (Cd) is a well-known nephrotoxic agent. Cd-induced renal dysfunction has been considered as one of the causes leading to the development of hypertension. The correlation between Cd concentration in blood and urine and cardiovascular diseases has been discussed in many epidemiological studies. A therapy with chelating agents is utilized for the treatment of toxic metal intoxication. Herein we present novel information indicating that monensin (applied as tetraethylammonium salt) is a promising chelating agent for the treatment of Cd-induced renal and cardiac dysfunction. The study was performed using the ICR mouse model. Adult ICR male mice were divided into three groups with six animals in each group: control (received distilled water and food ad libitum for 28 days); Cd-intoxicated (treated orally with 20 mg/kg b.w. Cd(II) acetate from day 1 to day 14 of the experimental protocol), and monensin treated group (intoxicated with Cd(II) acetate as described for the Cd-intoxicated group followed by oral treatment with 16 mg/kg b.w. tetraethylammonium salt of monensic acid for 2 weeks). Cd intoxication of the animals resulted in an increase of the organ weight/body weight indexes. Cd elevated significantly creatinine and glucose level in serum. Monensin treatment improved the organ weight/body weight ratios. The therapy of the Cd-intoxicated animals with monensin ameliorated the creatinine and glucose level in serum and decreased the concentration of the toxic metal ions in the heart and kidneys by 54% and 64%, respectively.

D-Penicillamine tripodal derivatives as efficient copper(I) chelators.

New tripodal metal-chelating agents derived from nitrilotriacetic acid (NTA) and extended by three unnatural amino acids D-penicillamine (D-Pen) are presented. D-Pen is actually the drug most extensively used to treat copper (Cu) overload in Wilson's disease and as such is a very attractive building block for the design of chelating agents. D-Pen is also a bulkier analogue of cysteine, with the β-methylene hydrogen atoms replaced by larger methyl groups. The hindrance of the gem-dimethyl group close to the thiol functions is demonstrated to influence the speciation and stability of the metal complexes. The ligands L(4) (ester) and L(5) (amide) were obtained from NTA and commercial D-Pen synthons in four and five steps with overall yields of 14 and 24%, respectively. Their ability to bind Cu(I), thanks to their three thiolate functions, has been investigated using both spectroscopic and analytical methods. UV, CD, and NMR spectroscopy and mass spectrometry evidence the formation of two Cu(I) complexes with L(5): the mononuclear complex CuL(5) and one cluster (Cu2L(5))2. In contrast, the bulkier ethyl ester derivative L(4) cannot accommodate the mononuclear complex in solution and thus forms exclusively the cluster (Cu2L(4))2. Cu K-edge X-ray absorption spectroscopy (XAS and EXAFS) confirms that Cu(I) is bound in trigonal-planar sulfur-only environments in all of these complexes with Cu- - -S distances ranging from 2.22 to 2.23 Å. Such C3-symmetric CuS3 cores are coordination modes frequently adopted in Cu(I) proteins such as metallothioneins. These two ligands bind Cu(I) tightly and selectively, which makes them promising chelators for intracellular copper detoxification in vivo.

ChemInform Abstract: Matching Chelators to Radiometals for Radiopharmaceuticals

AbstractReview: 321 refs.

Matching chelators to radiometals for radiopharmaceuticals

Radiometals comprise many useful radioactive isotopes of various metallic elements. When properly harnessed, these have valuable emission properties that can be used for diagnostic imaging techniques, such as single photon emission computed tomography (SPECT, e.g.(67)Ga, (99m)Tc, (111)In, (177)Lu) and positron emission tomography (PET, e.g.(68)Ga, (64)Cu, (44)Sc, (86)Y, (89)Zr), as well as therapeutic applications (e.g.(47)Sc, (114m)In, (177)Lu, (90)Y, (212/213)Bi, (212)Pb, (225)Ac, (186/188)Re). A fundamental critical component of a radiometal-based radiopharmaceutical is the chelator, the ligand system that binds the radiometal ion in a tight stable coordination complex so that it can be properly directed to a desirable molecular target in vivo. This article is a guide for selecting the optimal match between chelator and radiometal for use in these systems. The article briefly introduces a selection of relevant and high impact radiometals, and their potential utility to the fields of radiochemistry, nuclear medicine, and molecular imaging. A description of radiometal-based radiopharmaceuticals is provided, and several key design considerations are discussed. The experimental methods by which chelators are assessed for their suitability with a variety of radiometal ions is explained, and a large selection of the most common and most promising chelators are evaluated and discussed for their potential use with a variety of radiometals. Comprehensive tables have been assembled to provide a convenient and accessible overview of the field of radiometal chelating agents.

Preclinical evaluation of NETA-based bifunctional ligand for radioimmunotherapy applications using 212Bi and 213Bi: Radiolabeling, serum stability, and biodistribution and tumor uptake studies

Despite the great potential of targeted α-radioimmunotherapy (RIT) as demonstrated by pre-clinical and clinical trials, limited progress has been made on the improvement of chelation chemistry for (212)Bi and (213)Bi. A new bifunctional ligand 3p-C-NETA was evaluated for targeted α RIT using (212)Bi and (213)Bi. Radiolabeling of 3p-C-NETA with (205/6)Bi, a surrogate of (212)Bi and (213)Bi, was evaluated at pH5.5 and room temperature. In vitro stability of the (205/6)Bi-3p-C-NETA-trastuzumab conjugate was evaluated using human serum (pH7, 37 °C). Immunoreactivity and specific activity of the (205/6)Bi-3p-C-NETA-trastuzumab conjugate were measured. An in vivo biodistribution study was performed to evaluate the in vivo stability and tumor targeting properties of the (205/6)Bi-3p-C-NETA-trastuzumab conjugate in athymic mice bearing subcutaneous LS174T tumor xenografts. The 3p-C-NETA-trastuzumab conjugate was extremely rapid in complexing with (205/6)Bi, and the corresponding (205/6)Bi-3p-C-NETA-trastuzumab was stable in human serum. (205/6)Bi-3p-C-NETA-trastuzumab was prepared with a high specific activity and retained immunoreactivity. (205/6)Bi-3p-C-NETA-trastuzumab conjugate displayed excellent in vivo stability and targeting as evidenced by low normal organ and high tumor uptake. The results of the in vitro and in vivo studies indicate that 3p-C-NETA is a promising chelator for RIT applications using (212)Bi and (213)Bi. Further detailed in vivo evaluations of 3p-C-NETA for targeted α RIT are warranted.

Guanidylated hollow fiber membranes based on brominated poly (2,6-dimethyl-1,4-phenylene oxide) (BPPO) for gold sorption from acid solutions

Novel guanidylated hollow fiber membranes are prepared based on brominated poly (2,6-dimethyl-1,4-phenylene oxide) (BPPO) under mild reaction conditions. 1H-pyrazole-1-carboxamidine hydrochloride (HPCA) is employed for the guanidylation in aqueous solution at room temperature. The obtained guanidylated PPO hollow fiber membranes (GPPO HFMs) contain 0.31–0.95mmol/g guanidyl groups and show high affinity to tetrachloroauric anions (AuCl4−) in acid solutions. For 0.1M HCl solution containing 57.8mg gold/L, the sorption amount can get as high as 130mg/g. Besides, the GPPO HFMs show preferable selectivity toward gold in multicomponent solution containing Mg(II), Fe(III), Co(II), Ni(II), Cu(II), Zn(II) and Pb(II). A system of comparison experiments involving the sorption behavior of GPPO HFMs and quaternary aminated HFMs are also performed. The results reveal that driving forces for the high adsorption of gold mainly involve complexation mechanism. Overall, the obtained GPPO HFM is a promising chelating material for the recovery of gold.

Nucleoside-5′-phosphorothioate analogues are biocompatible antioxidants dissolving efficiently amyloid beta–metal ion aggregates

Amyloid beta (Aβ) peptide is known to precipitate and form aggregates with zinc and copper ions in vitro and, in vivo in Alzheimer's disease (AD) patients. Metal-ion-chelation was suggested as therapy for the metal-ion-induced Aβ aggregation, metal-ion overload, and oxidative stress. In a quest for biocompatible metal-ion chelators potentially useful for AD therapy, we tested a series of nucleoside 5'-phosphorothioate derivatives as re-solubilization agents of Cu(+)/Cu(2+)/Zn(2+)-induced Aβ-aggregates, and inhibitors of Fenton reaction in Cu(+) or Fe(2+)/H(2)O(2) system. The most promising chelator in this series was found to be APCPP-γ-S. This nucleotide was found to be more efficient than EDTA in re-solubilization of Aβ(40)-Cu(2+) aggregates as observed by the lower diameter, d(H), (86 vs. 64 nm, respectively) obtained in dynamic light scattering measurements. Likewise, APCPP-γ-S dissolved Aβ(40)-Cu(+) and Aβ(42)-Cu(2+)/Zn(2+) aggregates, as monitored by (1)H-NMR and turbidity assays, respectively. Furthermore, addition of APCPP-γ-S to nine-day old Aβ(40)-Cu(2+)/Zn(2+) aggregates, resulted in size reduction as observed by transition electron microscopy (diameter reduction from 2.5 to 0.1 μm for Aβ(40)-Cu(2+) aggregates). APCPP-γ-S proved to be more efficient than ascorbic acid and GSH in reducing OH radical production in Fe(2+)/H(2)O(2) system (IC(50) values 85, 216 and, 92 μM, respectively). Therefore, we propose APCPP-γ-S as a potential AD therapy capable of both reducing OH radical production and re-solubilization of Aβ(40/42)-M(n+) aggregates.

Preclinical evaluation of anti-HER2 Affibody molecules site-specifically labeled with 111In using a maleimido derivative of NODAGA

Affibody molecules have demonstrated potential for radionuclide molecular imaging. The aim of this study was to synthesize and evaluate a maleimido derivative of the 1,4,7-triazacyclononane-1-glutaric acid-4,7-diacetic acid (NODAGA) for site-specific labeling of anti-HER2 Affibody molecule. The maleimidoethylmonoamide NODAGA (MMA-NODAGA) was synthesized and conjugated to Z(HER2:2395) Affibody molecule having a C-terminal cysteine. Labeling efficiency, binding specificity to and cell internalization by HER2-expressing cells of [(111)In-MMA-NODAGA-Cys(61)]-Z(HER2:2395) were studied. Biodistribution of [(111)In-MMA-NODAGA-Cys(61)]-Z(HER2:2395) and [(111)In-MMA-DOTA-Cys(61)]-Z(HER2:2395) was compared in mice. The affinity of [MMA-NODAGA-Cys(61)]-Z(HER2:2395) binding to HER2 was 67 pM. The (111)In-labeling yield was 99.6%±0.5% after 30 min at 60°C. [(111)In-MMA-NODAGA-Cys(61)]-Z(HER2:2395) bound specifically to HER2-expressing cells in vitro and in vivo. Tumor uptake of [(111)In-MMA-NODAGA-Cys(61)]-Z(HER2:2395) in mice bearing DU-145 xenografts (4.7%±0.8% ID/g) was lower than uptake of [(111)In-MMA-DOTA-Cys(61)]-Z(HER2:2395) (7.5%±1.6% ID/g). However, tumor-to-organ ratios were higher for [(111)In-MMA-NODAGA-Cys(61)]-Z(HER2:2395) due to higher clearance rate from normal tissues. MMA-NODAGA is a promising chelator for site-specific labeling of targeting proteins containing unpaired cysteine. Appreciable influence of chelators on targeting properties of Affibody molecules was demonstrated.

Characterization of 99mTc(CO)3-iminodiacetic acid (IDA) and its comparison with 99mTc-(IDA)2 using compounds for hepatobiliary scintigraphy

The organometallic precursor of fac-[99mTc(CO)3(H2O)3]+ has attracted much attention because of the robustness and small size of Tc(I)-tricarbonyl complexes compared to Tc(V) complexes and the good labeling affinity with a variety of donor atoms. Among various ligand systems, an iminodiacetic acid (IDA) was proven as a good chelating group to form a Tc(III)-compelx as well as has been shown its potential as a chelating system for fac-[99mTc(CO)3] precursor. In an attempt to confirm the similarity and the difference between 99mTc(CO)3-IDA and 99mTc-(IDA)2-complex, M(CO)3-IDA (M = 99mTc, Re) complexes of disofenin, mebrofenin and N-(3-iodo-2,4,6-trimethyl phenylcarbamoylmethyl) iminodiacetic acid were prepared, and the biological evaluation of 99mTc(CO)3-disofenin was performed. The 99mTc(CO)3-IDA complexes were prepared with a high radiolabeling yield (>98%) in a quantitative manner and showed a negative charge. The in vivo pharmacokinetic behavior of 99mTc(CO)3-disofenin showed a similar biological activity to 99mTc-(disofenin)2 in that those complexes were quickly cleared from the blood by the hepatocytes and excreted into the gallbladder and intestine. Accordingly, the 99mTc(CO)3-IDA derivatives of disofenin and mebrofenin might be used as hepatobiliary imaging agents. Since an IDA is a promising chelator for 99mTc-based radiopharmaceutical and the biological properties of 99mTc(CO)3-IDA derivative shows similar to that of 99mTc-complex, a biomolecule containing IDA can be freely radiolabeled with fac-[99mTc(CO)3]-precursor or 99mTc. However, the radiolabeling efficiency and the biological behavior demonstrates the favorable properties of 99mTc(CO)3-IDA compound for the development of a new imaging agent.

Capreomycin — A polypeptide antitubercular antibiotic with unusual binding properties toward copper(II)

Capreomycin is an important therapeutic agent having intriguing and diverse molecular features. Its polypeptidic structure rich in nitrogen donors makes the drug a promising chelating agent for a number of transition metal ions, especially for copper(II). The results of the model investigational studies suggest that capreomycin anchors Cu 2+ ion with an amino function of the α,β-diaminopropionic acid residue at pH around 5. At physiological pH copper(II) ion is coordinated by two deprotonated amide nitrogen atoms of the α,β-diaminopropionic acid, the serine residue as well as the amino function deriving from the β-lysine. Above that pH value we observe a rearrangement within the coordination sphere leading to movement of Cu 2+ to the center of the peptide ring with concurrent coordination of four nitrogen donors. Spin–lattice relaxation enhancements and potentiometric measurements clearly indicate that deprotonated amide nitrogen atom from the β-ureidodehydroalanine moiety is the fourth donor atom.

Efficient Bifunctional Decadentate Ligand 3p-C-DEPA for Targeted α-Radioimmunotherapy Applications

A new bifunctional ligand 3p-C-DEPA was synthesized and evaluated for use in targeted α-radioimmunotherapy. 3p-C-DEPA was efficiently prepared via regiospecific ring opening of an aziridinium ion and conjugated with trastuzumab. The 3p-C-DEPA-trastuzumab conjugate was extremely rapid in binding (205/6)Bi, and the corresponding (205/6)Bi-3p-C-DEPA-trastuzumab complex was stable in human serum. Biodistribution studies were performed to evaluate in vivo stability and tumor targeting of (205/6)Bi-3p-C-DEPA-trastuzumab conjugate in tumor bearing athymic mice. (205/6)Bi-3p-C-DEPA-trastuzumab conjugate displayed excellent in vivo stability and targeting as evidenced by low organ uptake and high tumor uptake. The results of the in vitro and in vivo studies indicate that 3p-C-DEPA is a promising chelator for radioimmunotherapy of (212)Bi and (213)Bi.

Ethylenediamine-N,N’-diglutaric acid (EDDG) as a promising biodegradable chelator: Quantification, complexation and biodegradation

[S,S]-ethylenediamine-N,N’-diglutaric acid (EDDG) has been gaining interest in the industrial sector as a promising chelator. In this study, the effective metal complexing capacity of EDDG over a wide pH range was modelled and its biodegradability assessed. Results showed that EDDG could effectively bind to several metallic ions in a wide pH range and was completely biodegraded after approximately 15 days by un-acclimatized sludge. To confirm its biodegradability, an accurate quantification method based on the combination of liquid chromatography and tandem quadrupole mass spectrometry (LC-MS/MS) was developed. Good linearity of the detector response was found for EDDG at concentrations ranging from 0,15 to 1,2 mg/L.